Pano News
Subscribe
FDA GLP-1 Safety Review· Day 2

GLP-1 Warnings Detail Vision-Loss Risk

FDA-required GLP-1 warnings address a rare eye condition that can cause blindness.

November 10, 2026 · Updated Nov 10, 3:18pm ET

34%

Left · 4

33%

Center · 4

33%

Right · 4

Pano counted 12 articles from 11 outlets: 34% left-leaning, 33% center and 33% right-leaning. Pano rates the coverage Balanced.

What happened

  • The FDA’s required warnings for GLP-1 medicines address a rare eye condition that can cause sudden, permanent vision loss.
  • Called NAION, the condition involves reduced blood flow to the optic nerve and can cause painless vision loss in one eye, with no known treatment to reverse it.
  • The American Academy of Ophthalmology said any added risk appears small and that the drugs have not been established as a cause of NAION.
  • The academy advised patients not to stop their medication without consulting a doctor and to seek prompt eye care for sudden, painless vision loss.
  • Manufacturers must add the warnings, while whether and how GLP-1 drugs might cause the condition remains unresolved.

How the left told it

Left-leaning outlets emphasized the rare but potentially permanent vision-loss risk behind the warnings. The Guardian highlighted sudden blindness, while HuffPost described a “possible rare side effect.” The Washington Post added reassurance, quoting ophthalmologist Manjot Gill, who said the risk is “very, very low” and urged patients to discuss it with doctors.

How the right told it

Right-leaning outlets emphasized the new labeling requirement and the rare risk of permanent vision loss. Fox Business described a “small risk” and detailed the FDA’s trial review; Just the News likewise stressed rarity. ZeroHedge used stronger language, saying the FDA “Slaps” an “Eye Stroke” warning on the drugs.

FDA GLP-1 Safety Review

Storyline →
  1. Nov 10GLP-1 Warnings Detail Vision-Loss Risk (this story)Balanced
  2. Nov 9FDA Orders GLP-1 WarningBalanced

Topics in this story